Please assess the completion status of the following clinical trial:

Trial Title: P3 (Prepared, Protected, emPowered)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Are aged 16-24~* Were assigned male sex at birth~* Report sex with men or transgender women~* Are able to speak and read English~* Have reliable daily access to an Android or iOS smartphone with a data plan~* Are HIV-uninfected (self-report)~* Are not currently on PrEP but plan to initiate in the next 7 days and have an active PrEP prescription (prescription confirmed by study staff) OR on PrEP have an active PrEP prescription (prescription confirmed by study staff)~* Recruited from one of 9 subject recruitment venues (SRV) cities (Atlanta, Georgia; Boston, Massachusetts; Bronx, New York; Chicago, Illinois; Houston, Texas; Philadelphia, Pennsylvania; Tampa, Florida; Chapel Hill, NC; Charlotte, NC)~Exclusion Criteria:~* Aged younger than 15 years or older than 24 years~* Not available to meet with project staff for planned study visit(s)~* Non-English speaking~* Living with HIV~* Not currently prescribed PrEP (study staff unable to verify participant has an active PrEP prescription by a health provider)~* Anticipate not having reliable access to a smartphone with a data plan for 2 or more days during field testing or 1 or more weeks during the RCT intervention period~* Planning to move out of study area during the study period~* Unwilling or unable to comply with protocol requirements.~* Participated in field trial phase of P3 study~* Unable to be consented due to active substance use or psychological condition.

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- P3 (Type: EXPERIMENTAL): Participants will use P3
- P3+ (Type: EXPERIMENTAL): Participants will use P3+
- Control (Type: PLACEBO_COMPARATOR): Participants will receive the standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).